Multicenter retrospective study of efficacy of the combination of cetuximab and paclitaxel in patients with recurrent and/or metastatic oral squamous cell carcinoma

Multicenter retrospective study of efficacy of the combination of cetuximab and paclitaxel in patients with recurrent and/or metastatic oral squamous cell carcinoma - Retrospective study of the efficacy of the combination of cetuximab and paclitaxel

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029351

Enrollment

Registered

2017-09-29

Start date

2017-09-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent and/or metastatic oral squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The oral cavity is a primary site, and radical surgery is performed on the primary tumor. 2. It has been confirmed pathologically that it is squamous cell carcinoma. 3. Cet + PTX therapy is in effect as a target lesion of recurrence / metastatic lesion. 4. At least 1 year has elapsed regardless of the presence or absence of an event from the start of administration. 5. Age is over 20 years old.

Exclusion criteria

Exclusion criteria: 1. Before December 2012 there is a treatment history with Cetuximab. 2. Besides oral cancer, it has serious complications affecting life prognosis 3. Other patients whose research managers judged inappropriate as subjects.

Design outcomes

Primary

Measure	Time frame
Response rate of the combination of Cetuximab+ Paclitaxel therapy from the treatment start	—

Secondary

Measure	Time frame
One year progression free survival and overall survival	—

Countries

Japan

Contacts

Public ContactTomofumi Naruse

Nagasaki university Department of clinical oral oncology

naruse12@nagasaki-u.ac.jp095-819-7698

Outcome results